Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Operations (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Cash from Operations data on record, last reported at 13042000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 27.84% year-over-year to 13042000.0; the TTM value through Dec 2025 reached 55312000.0, down 68.4%, while the annual FY2025 figure was 55312000.0, 68.4% down from the prior year.
  • Cash from Operations reached 13042000.0 in Q4 2025 per CTNM's latest filing, down from 12197000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 40674000.0 in Q2 2023 and bottomed at 15661000.0 in Q2 2025.
  • Average Cash from Operations over 3 years is 5734000.0, with a median of 9350500.0 recorded in 2024.
  • The widest YoY moves for Cash from Operations: up 4.69% in 2024, down 120.9% in 2024.
  • A 3-year view of Cash from Operations shows it stood at 10704000.0 in 2023, then increased by 4.69% to 10202000.0 in 2024, then dropped by 27.84% to 13042000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 13042000.0 in Q4 2025, 12197000.0 in Q3 2025, and 15661000.0 in Q2 2025.